Sector: Health Care
Director information for BECTON DICKINSON (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bertram L. Scott | Former Chief Executive Officer, Affinity Health Plan | 74 | [] | [] | 2025 |
| Catherine M. Burzik | Chair | [] | [] | 2025 | |
| Christopher Jones | Former Chief Executive Officer, JWT Worldwide; Chair | 70 | ["Important international perspective based on distinguished career as a marketing leader", "Substantial marketing expertise", "Strategic and managerial expertise", "Served as Chief Executive Officer of JWT Worldwide from 1996 to 2001", "Chair of The Pew Charitable Trusts Board of Trustees", "Advisor and Board of Directors member at Nardello & Co.", "Board Chair of Newrotex Ltd."] | ["Audit", "Corporate Governance and Nominating (Chair)"] | 2025 |
| Claire M. Fraser, Ph.D. | Former Director, Institute for Genome Sciences. University of Maryland School of Medicine | 70 | [] | [] | 2025 |
| Dr. Byington | ["Extensive knowledge in integrated delivery of healthcare services", "Leadership positions at large health systems", "Strong executive management skills", "Strategic planning experience", "Expertise in clinical practice, infectious diseases and diagnostic systems", "Serves as Professor at University of California, San Diego since 2024", "Served as Special Advisor to the President of University of California Health from 2023 to 2024", "Served as Executive Vice President of University of California Health from 2019 to 2023", "Previously served as Dean of the College of Medicine and Senior Vice President at Texas A&M University from 2017 to 2019", "Previously served at the University of Utah from 1995 to 2016"] | ["Audit", "Quality and Regulatory"] | 2025 | ||
| Dr. Fraser | ["Internationally recognized scientist in genomics, infectious diseases and molecular diagnostics", "Established and led two large research institutes for over 30 years", "Experience as a director of several biotechnology companies and non-profit organizations", "Served as Director of the Institute for Genome Sciences and Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine from 2007 to 2024", "Previously served as President and Director of The Institute for Genomic Research from 1998 to 2007", "Previously served as Chair of the Board and a Director of the American Association for the Advancement of Science", "Member of the National Academy of Sciences and National Academy of Medicine", "Previously served as a Director of Ohana Biosciences Inc. and Helicos Biosciences Corp.", "Public directorships include Seres Therapeutics, Inc."] | ["Compensation and Human Capital", "Corporate Governance and Nominating"] | 2025 | ||
| Dr. Waldstreicher | Director | ["Over 30 years of experience in clinical and strategic leadership roles", "Emphasis on clinical development, product development strategy, safety and regulatory affairs", "Faculty affiliate at New York University School of Medicine, Department of Population Health, Division of Medical Ethics", "Chief Medical Officer of Johnson & Johnson from 2012 to 2023", "Chief Medical Officer of Janssen Pharmaceutical Research and Development from 2009 to 2012", "Vice President and Senior Vice President of Global Drug Development at Janssen from 2002 to 2009", "Led endocrinology and metabolism clinical research at Merck Research Laboratories"] | ["Corporate Governance and Nominating", "Quality and Regulatory"] | 2025 | |
| Gregory J. Hayes | Former Executive Chairman and Chief Executive Officer, RTX Corporation; Former Executive Chairman and CEO, RTX Corporation; Special Advisor to the Chief Executive Officer | 65 | ["Substantial strategic, financial, operational and transactional expertise", "Strong corporate governance background", "Experience in domestic and international business", "extensive executive experience", "leadership of large and complex businesses", "transformative initiatives", "strong financial expertise", "strategic expertise", "operational expertise", "transactional expertise", "significant international experience", "corporate governance experience"] | ["Audit", "Compensation and Human Capital"] | 2025 |
| Jacqueline Wright | Former Senior Partner, Chief Technology and Platform Officer, McKinsey & Company | 65 | ["Extensive digital transformation experience", "Leadership expertise in the areas of cybersecurity and technology advancement", "Development of key customer experiences across multiple technology platforms", "Leadership expertise in cybersecurity", "Technology advancement and development of key customer experiences", "Senior Partner, Chief Technology and Platform Officer of McKinsey & Company", "Corporate Vice President and Chief Digital Officer, U.S. Business of Microsoft Corporation", "Chief Digital and Information Officer for HM Revenue & Customs", "Various roles at Microsoft Corporation, including Corporate Vice President, IT Strategic Enterprise Services", "Chief information officer roles for BP plc and General Electric Company", "Board member for Russell Reynolds Associates, Inc. and Frasers Group plc"] | ["Audit", "Compensation and Human Capital"] | 2025 |
| Jeffrey W. Henderson | Former Chief Financial Officer, Cardinal Health Inc.; Chair; President of JWH Consulting LLC | 61 | ["Experienced healthcare executive", "Deep knowledge of the industry", "Strong financial, strategic and operational expertise", "Significant international experience", "Valuable corporate governance experience", "Advisory Director to Berkshire Partners LLC", "Former Chief Financial Officer of Cardinal Health Inc.", "Held multiple positions at Eli Lilly and General Motors"] | ["Audit", "Compensation and Human Capital"] | 2025 |
| Joanne Waldstreicher, M.D. | Former Chief Medical Officer, Johnson & Johnson | 65 | [] | [] | 2025 |
| R. Andrew Eckert | Former Chief Executive Officer, Zelis Inc.; Director | 64 | ["Leader in healthcare information technology", "Extensive experience as an executive officer of several healthcare companies", "Knowledge of operations, strategic planning, product development and marketing", "Corporate governance insight from serving as CEO and board member of public companies", "Senior Advisor to Permira, a global private equity firm since 2023", "Board Chairman of Lytx, Inc. since July 2025", "Chief Executive Officer of Zelis Inc. from 2020 to 2021", "President and Chief Executive Officer of Acelity L.P. Inc. from 2017 until October 2019", "Chief Executive Officer of Valence Health, Inc. until October 2016", "Chief Executive Officer of TriZetto Corporation until November 2014"] | ["Compensation and Human Capital (Chair)", "Audit"] | 2025 |
| Robert L. Huffines | Former Global Chair, Investment Banking, J.P. Morgan Chase & Co.; Director | 60 | ["Substantial experience advising healthcare companies on strategy, mergers and acquisitions, divestitures and financing", "Knowledge of the healthcare industry", "Experienced healthcare executive with more than 30 years of experience advising healthcare companies.", "Knowledge of and experience in the healthcare industry.", "Leadership skills and perspectives from executive positions at J.P. Morgan Chase & Co.", "Served as Global Chair, Investment Banking of J.P. Morgan Chase & Co.", "Held multiple positions at J.P. Morgan Chase & Co.", "Various investment banking and advisory positions at Alex Brown & Sons."] | ["Audit", "Corporate Governance and Nominating"] | 2025 |
| Thomas E. Polen | Chairman, Chief Executive Officer and President, BD | 52 | ["Over 20 years with BD", "Oversight responsibility for all of BD's business segments", "Global research and development", "Innovation and operations", "Commercial organization of BD's Americas region", "Extensive industry experience and business expertise", "Particularly in strategy and innovation, marketing, technology"] | [] | 2025 |
| Timothy M. Ring | Former Chairman and Chief Executive Officer, C. R. Bard, Inc.; Director | 68 | ["20 years of experience in various leadership positions at C. R. Bard", "Chairman and Chief Executive Officer of C. R. Bard", "Expertise in strategy, product development, financial matters, international operations", "Extensive experience in the healthcare industry", "Co-founder of TEAMFund, Inc., an impact fund for medical technology"] | ["Audit", "Quality and Regulatory"] | 2025 |
| William M. Brown | Chairman and Chief Executive Officer, 3M Company; Chairman of 3M Company | 63 | ["veteran chief executive officer", "substantial strategic, financial, operational and innovation expertise", "strong corporate governance background", "experience in domestic and international business", "Chairman and Chief Executive Officer of 3M Company", "Executive Chair of L3Harris Technologies", "previously served as Chair, President and Chief Executive Officer of Harris Corporation", "joined Harris Corporation in November 2011", "served in a variety of leadership roles over 14 years at United Technologies Corporation"] | ["Compensation and Human Capital", "Corporate Governance and Nominating"] | 2025 |
